Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea

- August 2nd, 2018

Biomerica (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent application covering Biomerica’s compositions, devices and methods of IBS sensitivity testing. The patent is expected to issue before September 2018.

As quoted in the press release:

The patent application specifically applies to Biomerica’s InFoods® IBS product, which is currently in a clinical study in the U.S.  This patent would be the first for the InFoods® patent portfolio, providing patent protection for InFoods® IBS in Korea until 2035.

It is estimated that over 45 million Americans are affected by Irritable Bowel Syndrome (IBS).  The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair patient well-being and a person’s ability to function both at home and in the workplace.

Click here to read the full press release.

Read our FREE medical device report today



Get My Free Report  

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All



Leave a Reply